



Aureus Pharma extends its knowledge database agreement with sanofi-aventis R&D

Paris, France, November 5, 2009 -- Aureus Pharma, a leading provider of knowledge management solutions to accelerate discovery in the life sciences industry, announces today the extension of its knowledge database agreement with sanofi-aventis research & development for an additional three-year term.

Under the agreement, Aureus will provide new AurSCOPE® knowledge databases and continue to update existing databases for sanofi-aventis' R&D division. The Aureus Pharma databases will give sanofi-aventis researchers access to information on major therapeutic targets. These include GPCR protein receptors, nuclear receptors, kinase inhibitors, ion channels, as well as information relative to drug safety including data on ADME (absorption, distribution, metabolism, and excretion).

The new agreement reinforces the relationship between Aureus Pharma and sanofi-aventis, which has been in existence for seven years already. It also secures additional revenues for Aureus over the next three years.

"Sanofi-aventis' decision to extend the partnership for an additional three year period, as well as to acquire new knowledge bases, confirms the fact that Aureus' products are meeting the needs of the world's leading pharmaceutical companies," said Dr Jason Theodosiou, CEO of Aureus Pharma.

Aureus Pharma's information solutions are working for many of the world's most successful biopharmaceutical companies and prestigious research institutions.

About Aureus Pharma

Aureus Pharma, provides a range of scientific knowledge solutions enabling biopharmaceutical companies to better understand the relationships of biological targets to compounds under evaluation. Aureus experts continuously monitor and organize the most relevant information from the scientific literature, including experimental *in vitro* and *in vivo* protocols. This detailed knowledge forms the AurSCOPE® database line, focusing on the human body's main therapeutic targets: GPCRs, Kinases, Ion Channels, Proteases and Nuclear Receptors. Additional AurSCOPE® databases relate to safety, toxicology, and pharmacokinetics (ADME, hERG). Consolidating all the therapeutic targets, the AurSCOPE® Global Pharmacology Space (GPS) provides researchers with the most comprehensive available coverage of the "druggable" genome. Applications include AurQUEST®, the web-based query tool, DDI Predict® for drug-drug interactions, and AurPROFILER®, the compound profiling visualization tool. Headquartered in Paris, France, Aureus Pharma's information solutions are proven to streamline the discovery process for many of the world's most successful biopharmaceutical companies and prestigious research institutions.

See www.aureus-pharma.com for more information

Press and Analysts Contact

Andrew Lloyd & Associates

Neil Hunter / Andrew Lloyd

neil@ala.com / allo@ala.com

Tel +44 1273 675100
